[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"substance-use-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:substance-use-disorders":32},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,72,0,25,[9,46,76,96,128,153,180,206,232,256,281,310,339,363,389,415,436,457,478,524,552,583,608,645,676],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100476614","cars-cannabis-and-alcohol-reduction-study-100476614",false,"NCT05486234","CARS: Cannabis and Alcohol Reduction Study","Brief Computerized Intervention for Reducing Adolescent Cannabis and Alcohol Use","CARS","Inclusion Criteria:\n\n* between the ages of 13 and 17\n* be seeking treatment for either cannabis or alcohol use;\n* report co-occurring alcohol and cannabis use during the past three months (i.e., participants who report using both alcohol and cannabis during the three months prior to participation in the study, regardless of if the use was simultaneous)\n* have a caregiver willing to participate and provide consent.","ALL","13 Years","17 Years",{"count":22,"type":23},52,"ESTIMATED","INTERVENTIONAL",[26],"NA","The study will test a computerized treatment with subjects ages 13-17 years who are seeking treatment for alcohol and\u002For cannabis use. Follow-up assessments will be conducted at one- and three-months following treatment.",[29,30,31,32],"Cannabis Use","Alcohol Use, Unspecified","Substance Use","Substance Use Disorders","RECRUITING","2026-08-11",{"date":36,"type":37},"2026-08-13","ACTUAL",{"date":39,"type":37},"2023-01-25",{"date":41,"type":23},"2026-10-01",{"name":43,"class":44},"Medical University of South Carolina","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":24,"phases":57,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100647407","interprofessional-simulation-program-for-clinical-resilience-and-empathy-project-inspire-100647407","NCT07707115","Interprofessional Simulation Program for Clinical Resilience and Empathy: Project INSPIRE","Interprofessional Simulation Program for Clinical Resilience and Empathy (INSPIRE) for Healthcare Teams Caring for Birthing Individuals With Substance Use Disorder in Utah","INSPIRE","Inclusion Criteria:\n\n* Employed at the University of Utah Hospital\n* Directly interfaces with birthing individuals (as clinical or non-clinical team member, e.g., physician, nurse, emergency medical technician, social worker)\n* English speaking\n\nExclusion Criteria:\n\n* Unable to provide informed consent","18 Years",{"count":56,"type":23},300,[26],"The goal of this clinical trial is to develop and evaluate INSPIRE, an intervention for healthcare teams to improve care for individuals with substance use disorder (SUD) during their peri-delivery care. The main question it aims to answer is whether healthcare provider stigmas and behaviors change after receiving the training. The study will be implemented at the University of Utah.",[32,60,61,62,63],"Simulation Training","Pregnancy Related","Patient-centered Care","Bias, Implicit",[65,66],"substance use disorders","Care received in hospital during labor & delivery and post-partum","2026-08-05",{"date":69,"type":37},"2026-08-10",{"date":71,"type":37},"2026-08-01",{"date":73,"type":23},"2027-12-31",{"name":75,"class":44},"University of Utah",{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":24,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":45},"100639927","feasibility-of-an-interdisciplinary-intervention-to-improve-care-transitions-for-hospitalized-patients-with-substance-use-disorders-100639927","NCT07575373","Feasibility of an Interdisciplinary Intervention to Improve Care Transitions for Hospitalized Patients With Substance Use Disorders","Evaluating the Feasibility of an Interdisciplinary Primary Care-based Intervention to Improve Transitions to Follow-Up Care for Hospitalized Patients With Substance Use Disorders: A Pilot Randomized Controlled Trial","IntACT","Inclusion Criteria:\n\n* Aged 18 years and older\n* Hospitalized at University of Utah Medical Center (UUMC) for any medical reason, and\n* Electronic Health Record (EHR) documented diagnosis of any SUD.\n\nExclusion Criteria:\n\n* Currently incarcerated\n* Tobacco use as only documented substance use disorder",{"count":85,"type":23},75,[26],"The purpose of this study is to evaluate the feasibility and preliminary effectiveness of a primary care-based Interdisciplinary Addiction Care Transition (IntACT) team that will meet patients with substance use disorders (SUD) during a medical hospitalization and provide intensive care management, peer support, and interim SUD and medical care after discharge while facilitating a transition to long term community-based treatment.",[32],{"date":69,"type":37},{"date":91,"type":37},"2026-06-21",{"date":93,"type":23},"2027-09-15",{"name":95,"class":44},"Michael Incze",{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":24,"phases":106,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":45},"100296200","project-i-test-implementing-hiv-testing-in-opioid-treatment-programs-100296200","NCT03135886","Project I Test: Implementing HIV Testing in Opioid Treatment Programs","A Cluster RCT to Increase HIV Testing in Substance Use Treatment Programs","Inclusion Criteria:\n\n* Eligible sites must:\n\n  1. See at least 150 unduplicated patients\u002Fyear\u002Fsite\n  2. Be capable and willing to prospectively collect data on the number of patients who a) are offered any HIV and\u002For HCV tests; b) completed these tests; c) are referred to care\u002Fevaluation (and type of referral) if positive; and d) are linked to care\u002Fevaluation within 30 days of diagnosis\n  3. Be capable and willing to provide patient demographics, testing data within demographic categories of gender and race\u002Fethnicity (in aggregate) and data on HIV\u002FHCV test reimbursement processes and outcomes\n  4. Have key staff willing to consent to participate in study surveys, qualitative interviews and intervention coaching throughout the study\n\nExclusion Criteria:\n\n* Sites will be excluded if:\n\n  1. Over 50% of patients served in the prior 6 months were HIV or HCV tested\n  2. They are terminated via PI decision\u002Fdiscretion",true,{"count":105,"type":23},418,[26],"This study will test two active evidence-based \"practice coaching\" (PC) interventions to improve opioid treatment programs' (OTPs') provision and sustained implementation of on-site 1) HIV testing and linkage to care and 2) HIV\u002FHepatitis C virus (HCV) testing and linkage to care among patients seeking\u002Freceiving substance use disorder treatment.\n\nAims are:\n\nAim 1: To evaluate the effectiveness of the PC interventions on improving patient uptake of HIV testing in OTPs including the incremental impact of the HIV\u002FHCV intervention on HIV testing.\n\nAim 2: To examine, using mixed-methods, the impact of the PC interventions on the initiation and sustained provision of HIV testing and timely linkage to care.\n\nAim 3: To evaluate the health outcomes, health care utilization, and cost-effectiveness of the PC interventions compared incrementally to one another and to the control condition.\n\nPrimary Hypothesis:\n\n1. The two PC interventions will result in significantly higher proportions of patients tested for HIV than the information control condition during the \"initial impact\" period (7-12 months post-randomization or T3), controlling for the proportion of patients tested during the baseline period, T1 (Primary) and during the \"sustained impact\" period, 13-18 months post-randomization or T4 (Secondary).\n2. The HIV\u002FHCV PC intervention will result in significantly higher proportions of patients tested for HIV than the HIV PC intervention during the initial impact period (7-12 months post-randomization or T3), controlling for the proportion of patients tested during the baseline period, T1 (Secondary) and during the \"sustained impact\" period, 13-18 months post-randomization or T4 (Secondary).",[109,110,32,111],"HIV\u002FAIDS","Hepatitis C","Opioid-use Disorder",[113,114,115,116,117,118,119],"HIV","HIV Testing","Hepatitis C Virus Testing","Opioid Use Disorder Treatment","Substance Use Disorders Treatment","Hepatitis C Virus","Practice Coaching",{"date":121,"type":37},"2026-08-07",{"date":123,"type":37},"2017-06-12",{"date":125,"type":23},"2026-08-31",{"name":127,"class":44},"Columbia University",{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":24,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":45},"100606638","enhancing-addiction-treatment-through-psychoeducation-100606638","NCT07178158","Enhancing Addiction Treatment Through Psychoeducation","Enhancing Addiction Treatment Through Psychoeducation: Evaluating the Feasibility and Acceptability of a Neuroscience-Informed Mobile App","Inclusion Criteria:\n\n* current DSM-5 opioid and\u002For stimulant use disorder\n* currently on medication treatment for SUD\n* owning a smartphone with sufficient functionality to download and utilize the NIPA app.\n\nExclusion Criteria:\n\n* current psychosis, mania, or suicidal\u002Fhomicidal ideation\n* non-English speaking","65 Years",{"count":137,"type":23},40,[26],"Addiction is a brain disorder characterized by a broad range of both apparent and subtle cognitive impairments in attention, memory, executive functions, and decision-making. These cognitive problems are clinically significant and may contribute to poor treatment outcomes in people with Substance Use Disorders (SUDs), such as a high risk of dropout, low treatment compliance, and shorter periods of abstinence. Studies on cognitive function in SUDs reveal that chronic use of drugs and alcohol can also negatively affect another crucial component of cognition: awareness, or metacognition. Metacognition is defined as an individual's ability to perceive and understand their cognitive functions and use this understanding to regulate them. One of the key consequences of metacognitive impairments is the lack of insight in people with SUDs, which adversely affects treatment outcomes. Substance users with poor metacognition are more reluctant to initiate or continue treatment and are more likely to deny their cognitive problems. Therefore, improving metacognition may remove or reduce motivational barriers to invest time and effort in the recovery process in general, and in the brain recovery process specifically. Despite the importance of neurocognition and metacognition in the recovery process for substance users, there is a dearth of interventions designed to target these functions.",[32],[142,143,144],"tES\u002FTMA: Transcranial electrical stimulation","CT: Cognitive Training","DASES: Drug Abstinence Self-Efficacy Scale","2026-08-04",{"date":121,"type":37},{"date":148,"type":37},"2026-07-23",{"date":150,"type":23},"2027-04-30",{"name":152,"class":44},"Virginia Commonwealth University",{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":24,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":176,"leadSponsor":178,"locationsCount":45},"100649616","promoting-recovery-by-overcoming-self-stigma-in-mental-health-disorders-with-a-narrative-enhancement-and-cognitive-therapy-nect-group-intervention-100649616","NCT07735481","Promoting Recovery by Overcoming Self-stigma in Mental Health Disorders With a Narrative Enhancement and Cognitive Therapy (NECT) Group Intervention","Promoting Recovery by Overcoming Self-stigma in Mental Health Disorders With a Narrative Enhancement and Cognitive Therapy (NECT) Group Intervention - A Randomized Controlled Trial and Qualitative Study","Inclusion Criteria:\n\n* Written informed consent\n* DSM-5 psychiatric diagnosis within F10-F48, F60-F69, or F90, including substance use disorders\n* Receiving outpatient or day-hospital treatment\n* Diagnosed or in treatment for at least 12 months\n* Clinically stable for at least 3 months, with stable pharmacological treatment during this period\n* Clinical Global Impressions-Severity score below 6\n\nExclusion Criteria:\n\n* Participation in another program likely to affect social functioning or self-stigma, such as social cognitive remediation or social skills training\n* Acute psychiatric episode with a Clinical Global Impressions-Severity score above 6\n* Medical emergency or immediate life-threatening situation at inclusion\n* Unable to provide informed consent\n* Comorbid intellectual disability\n* Receiving care under constraint or deprived of liberty by judicial order Insufficient ability to speak and read French",{"count":161,"type":23},106,[26],"This study will evaluate whether Narrative Enhancement and Cognitive Therapy (NECT) can promote recovery among adults living with severe mental health disorders, including substance use disorders. NECT is a structured group intervention that combines education about stigma, cognitive techniques to challenge internalized negative beliefs, and narrative exercises that help participants develop a broader identity beyond their diagnosis.\n\nApproximately 106 adults receiving outpatient or day-hospital psychiatric care at Geneva University Hospitals will be randomly assigned to receive either usual care plus 12 weekly NECT sessions or usual care plus 12 comparison group sessions that do not specifically address self-stigma or recovery. The study will examine whether NECT improves recovery after the intervention and whether any benefits are maintained over time.",[165,32],"Mental Disorders",[167,168,169,170,171],"Narrative Enhancement and Cognitive Therapy","Self stigma","Recovery","Substance use disorders","Transdiagnostic group intervention","NOT_YET_RECRUITING","2026-08-03",{"date":67,"type":37},{"date":41,"type":23},{"date":177,"type":23},"2029-09-30",{"name":179,"class":44},"Louise Penzenstadler",{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":103,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":24,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":45},"100501659","copeweb-training-for-providers-100501659","NCT05812131","COPEWeb Training for Providers","Web-Based Provider Training for Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPEWeb)","COPEWeb","Inclusion Criteria:\n\n* currently a provider in a behavioral health field (e.g., psychology, psychiatry, counseling)\n* English speaking\n* able to consistently obtain reliable internet access\n* willing to attend a 2-day \"live\" in-person (or virtual) COPE training if randomly assigned to that condition\n* willing to engage in a standardized patient assessment after training\n* has no prior formal training in the COPE therapy\n\nExclusion Criteria:\n\n* received prior training in COPE\n* not a provider in the behavioral health field\n* non-English speaking\n* lack of reliable internet access",{"count":189,"type":23},248,[26],"Post-traumatic stress disorder (PTSD) and substance use disorders (SUD) are two of the most common and debilitating mental health conditions afflicting military Veterans. PTSD and SUD frequently co-occur and are associated with poorer treatment outcomes. The investigators' team developed a trauma-focused intervention, Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE), which is identified by the VA as a gold standard of behavioral healthcare and was designated as a first-line treatment in the 2025 APA Clinical Practice Guideline for PTSD. However, a critical barrier to ensuring that Veterans with co-occurring PTSD\u002FSUD receive evidence-based treatment is a lack of provider training. This project directly addresses this critical gap by developing a new web-based training program for providers (COPEWeb).",[193,32],"PTSD",[193,65,195,196],"training","providers",{"date":198,"type":37},"2026-08-06",{"date":200,"type":37},"2025-05-11",{"date":202,"type":23},"2027-04-05",{"name":204,"class":205},"VA Office of Research and Development","FED",{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":213,"enrollmentInfo":214,"targetDuration":4,"studyType":24,"phases":216,"briefSummary":217,"conditions":218,"keywords":221,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":45},"100609782","safe--sound-protocol-in-adults-with-trauma-and-sud-100609782","NCT07219056","Safe & Sound Protocol in Adults With Trauma and SUD","The Effect of the Safe and Sound Protocol on Emotional Regulation in Traumatized Adults With Substance Use Disorders","Inclusion Criteria:\n\n* Ages 18 years old to 75 years old\n* In residential treatment for substance use disorder.\n* Has a history of trauma and is enrolled in Caron's trauma programming\n* Is proficient in English\n* Able to provide written informed consent.\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n\nExclusion Criteria:\n\n* Does not speak English\n* Age \\\u003C 18 or \\> 75\n* Does not have a history of trauma\n* Active psychosis\n* Active or uncontrolled seizures\n* Tinnitus\n* Active suicidal ideation\n* Actively engaging in self-injurious behavior\n* Severe neurological condition\n* Diagnosis of autism\n* Has any serious medical disease or mental health condition which, in the judgment of the Principal Investigator or his\u002Fher designee, would make study participation unsafe, or would make intervention compliance difficult.","75 Years",{"count":215,"type":23},100,[26],"This study will explore whether the use of the Safe and Sound Protocol (SSP) app is an effective adjunct to treatment as usual (TAU) in individuals with co-occurring substance use disorders and trauma. This study will recruit 129 participants (100 completers) randomized to receive either active or sham SSP in addition to TAU. Participants will utilize the SSP for a minimum of three hours to a maximum of five hours for a total of seven days. Data will be collected at both pre- and post-test. Data to be collected will include measures on affect, anxiety, personality, mindfulness, and posttraumatic stress disorder symptoms. The SSP has shown effectiveness in reducing symptoms of anxiety, depression, and trauma symptoms in pilot studies conducted at other locations. This will be the first study to examine the effectiveness of SSP with individuals with co-occurring SUD and trauma.",[32,219,220],"Posttraumatic Stress Symptom","Anxiety",[65,222,223],"posttraumatic stress symptoms","anxiety","2026-07-31",{"date":173,"type":37},{"date":227,"type":37},"2025-12-15",{"date":229,"type":23},"2027-03-15",{"name":231,"class":44},"Caron Treatment Centers",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":103,"sex":18,"minAge":54,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":24,"phases":240,"briefSummary":242,"conditions":243,"keywords":246,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":45},"100609743","phase-1-evaluation-of-the-safety-and-effects-of-psychoactive-substances-in-people-with-past-opioid-use-100609743","NCT07218549","Evaluation of the Safety and Effects of Psychoactive Substances in People With Past Opioid Use","Inclusion Criteria:\n\n1. English-speaking, 18- to 55-year-old males or females.\n2. Female subjects must have a negative serum pregnancy test at time of screening and negative urine pregnancy test upon admission. In addition, female subjects must meet one of the following conditions:\n\n   * Is a woman of non-childbearing potential defined as no menses for at least 12 months with status confirmed by FSH and estradiol levels at screening or surgically sterile at screening visit OR\n   * Is a woman of childbearing potential and using a contraceptive method that is highly effective, with a failure rate of \\\u003C1%, from Screening until 9 months after receiving the study medication. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the dose of study intervention.\n3. Male subjects must agree to the following from Day 1 until 9 months after receiving the study medication:\n\n   • Not donate fresh unwashed semen\n\n   Plus, either:\n   * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR\n   * Use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.\n   * Use a male condom when engaging in any activity that allows for passage of ejaculate to another person\n4. Physically healthy, as determined by a clinical interview with a physician, laboratory tests (urinalysis, blood chemistry, 12-lead ECG), physical examination, and self-reported medical history.\n5. No current or past diagnosis of severe mental illness, as determined by a clinical interview.\n6. Clinical laboratory test results (CMP, CBC, etc.) must be within the normal reference range or with acceptable deviations that are judged to be not clinically significant by a study physician.\n7. Have a history of self-reported recreational opioid use as defined by at least 10 times in the past year and at least once in the 12 weeks before screening.\n8. Able and willing to give signed informed consent, reliable, and willing to make themselves available for the study's duration and follow study procedures.\n9. Agree not to consume any recreational drugs during the study (THC is excluded).\n10. Able to perform study procedures as determined by clinical judgment.\n11. Able to meet eligibility requirements of the Qualification Phase (i.e., drug discrimination) and Naloxone Challenges.\n\nExclusion Criteria:\n\n1. Seeking treatment for a substance or alcohol use disorder as determined by self-report during the intake interview.\n2. Current or past diagnosis of opioid use disorder or other substance use disorder (SUD) within the past year, excluding THC and nicotine-containing products. With regard to marijuana\u002FTHC, an individual must be able to tolerate 48 hours of abstinence from marijuana\u002FTHC products.\n3. History of opioid overdose.\n4. Using medication or supplements that might interact with kratom or oxycodone as determined by self-report during intake interview.\n5. Treatment with any investigational drug during the last 30 days.\n6. Participants on parole or probation.\n7. Currently pregnant or trying to conceive or currently lactating as determined by blood pregnancy testing at screening, urine pregnancy testing at admission, and self-reporting during interview and study visits.\n8. Current or recent history of significant violent or suicidal behavior or suicidal\u002Fhomicidal risk as determined by the C-SSRS.\n9. Sensitivity, allergy, or contraindications\u002Fallergies to kratom, opioids, or similar compounds.\n10. Use prescription or nonprescription drugs and dietary supplements within seven days or five half-lives (whichever is longer) that, in the opinion of the study clinician may interfere with the investigational product.\n11. Positive urine drug screen (UDS) for substances of abuse at each admission in the Qualification and Treatment phases, excluding tetrahydrocannabinol (THC). If a participant presents with a positive UDS excluding THC at any admission or any visit, the investigator, at their discretion, may reschedule a repeat of UDS until the UDS is negative, excluding THC, before the participant is permitted to participate in any phase of the study.\n12. Positive alcohol breathalyzer test at each admission in the Qualification and Treatment Phase.\n13. History of sensitivity to heparin or heparin-induced thrombocytopenia.\n14. Has not donated blood or plasma within the last six weeks.\n15. Has a history of increased intracranial pressure or brain tumors.\n16. Has gastrointestinal obstruction, including paralytic ileus.\n17. Has a history of seizure disorders.\n18. Has a chronic obstructive pulmonary disease or cor pulmonale.\n19. Has a history of anemia or any other significant hematologic disorder.\n20. Has a condition or abnormality that, in the opinion of the PI or Study Physician, would compromise the safety of the patient or the quality of the data.\n21. Has a major surgery planned within the next 6 months.","55 Years",{"count":5,"type":23},[241],"PHASE1","The purpose of this study is to understand how kratom affects people. In this study, kratom will be compared with another substance and a placebo (an inactive substance). Researchers will also study how the substances move through and affect the body. This includes examining how the body absorbs, processes, and eliminates the drug (pharmacokinetics), as well as how the drug affects the body and how it may make you feel (pharmacodynamics). The information collected will help researchers better understand the effects and potential risks of kratom.",[244,32,245],"Opioid Use","Opioid Analgesia",[244,32],"2026-07-28",{"date":249,"type":37},"2026-07-30",{"date":251,"type":23},"2026-09-01",{"date":253,"type":23},"2029-05-31",{"name":255,"class":44},"Christopher D. Verrico",{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":263,"minAge":54,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":24,"phases":267,"briefSummary":268,"conditions":269,"keywords":270,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":45},"100504938","preconception-intervention-for-incarcerated-women-with-substance-use-100504938","NCT05854836","Preconception Intervention for Incarcerated Women With Substance Use","A Preconception Health Intervention to Reduce Substance Exposed Pregnancies Among Incarcerated Women","Inclusion Criteria:\n\n* English-speaking\n* Capable of becoming pregnant (did not undergo a permanent sterilization procedure and not using a highly effective long-acting reversible birth control method, i.e. intrauterine device or implant.)\n* During the three year prior to arrest or entering the treatment program engaged in vaginal sex with a male partner.\n* During the three months prior to arrest or entering the treatment program used at least one substance (heroin, fentanyl, opioids, cocaine, methamphetamine, or marijuana or alcohol with another substance).\n* (For women recruited from the MAT Program): Expected length of incarceration at the St. Louis County Jail 2-6 months; expected release into the community.\n\nExclusion Criteria:\n\n* Participated in a focus group that was part of the formative work for this study to create the intervention adaptation\n* Non-English-speaking\n* Not capable of pregnancy (underwent a permanent sterilization procedure or using a long-acting reversible contraceptive method)\n* No vaginal sex with a male partner in the 3 years prior to incarceration or entering the treatment program.\n* No use of an illicit substance, such as only alcohol or marijuana use not in combination with another substance","FEMALE","49 Years",{"count":266,"type":23},90,[26],"The goal of this pilot trial is to test the feasibility and acceptability as well as efficacy of the adapted intervention, CHOICES-PLEAS (Pregnancy Liberated from Exposure to Alcohol and Substances) among women will illicit polysubstance use participating in a court-mandated jail-based 90-day substance use disorder treatment program. The main questions it aims to answer are:\n\n1. What is the feasibility and acceptability of implementing the CHOICES-PLEAS intervention in a court-mandated jail-based substance use disorder treatment program?\n2. Does participation in CHOICES-PLEAS lower the risk of a substance exposed pregnancy at 1 and 3 months after release compared to a control condition?\n3. Does participation in CHOICES-PLEAS increase motivation to change substance use and reduce risky sexual behaviors at 1 and 3 months after release compared to a control condition? Participants will receive three one-on-one motivational interviewing sessions and one family planning referral visit during incarceration and one booster session at 1 month after release from jail.\n\nResearchers will compare the CHOICES-PLEAS intervention to a control condition to see if participation in the intervention reduces risk of substance exposed pregnancy, increases motivation to change substance use, and reduces risk of risky sexual behaviors.",[32],[32,271,272],"Preconception Health","Motivational Interviewing","2026-07-21",{"date":148,"type":37},{"date":276,"type":37},"2023-12-04",{"date":278,"type":23},"2027-03-01",{"name":280,"class":44},"St. Louis University",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":103,"sex":18,"minAge":287,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":24,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":309},"100609108","temporal-interference-methods-for-addiction-treatment-100609108","NCT07210268","Temporal Interference Methods for Addiction Treatment","Inclusion Criteria:\n\n* Between the ages of 21 and 50\n* Nicotine dependent and vape at least 15 mg nicotine per day\n* Must have a phone with internet access\n* Participants must have at least a 6th grade education and be able to speak and read English\n\nExclusion Criteria:\n\n* History of seizures, seizure disorders, or familial history of seizure disorders\n* History of intractable migraine or complicated migraine syndromes\n* History of suicide attempts or active suicidal ideation (past month)\n* History of cardiac arrhythmias, prolonged QT, pacemakers, or cardiovascular disorders\n* Hypertension with systolic BP \\>150mmHgCentral nervous system structural lesions (tumors, MS, strokes, etc.)\n* Active neuropsychiatric disorders (schizophrenia, bipolar, active psychosis, dementia, etc.)\n* History of head trauma with loss of consciousness, skull fractures, subdural hematomas\n* Active opioid, cocaine, and\u002For methamphetamine use\n* Active severe cannabis use disorder\n* Active alcohol use disorder or history of alcohol withdrawal\n* Metal implants in the head or under the scalp (excluding dental implants)\n* Current smoking cessation treatment or medications affecting reward processing\n* Pregnancy","21 Years","50 Years",{"count":290,"type":23},120,[26],"This clinical study is testing whether a new non-invasive brain stimulation method, called temporal interference (TI), can reduce nicotine cravings and usage in people who vape. TI delivers mild electrical currents to the scalp in a way that targets deep brain areas involved in addiction, without the need for surgery.\n\nIn this randomized controlled trial, participants will be assigned to one of three groups: TI stimulation to the nucleus accumbens, TI stimulation to the anterior insula, or a placebo (sham) condition. Each participant will attend a single stimulation session after 8 hours of nicotine abstinence and will use a custom vape device that measures real-time nicotine inhalation. Craving levels will be reported during and after the session.\n\nThe study aims to determine whether TI to the insula or nucleus accumbens is more effective at decreasing cravings and nicotine inhalation, and whether either is more effective than sham stimulation. For one week after the session, participants will use a smartphone app to track nicotine use and cravings. The primary hypothesis is that TI stimulation to deep brain regions will reduce both nicotine craving and actual use, immediately after stimulation and over the following week, compared to the sham condition.",[294,32],"Nicotine Use Disorder",[296,297,32,298,299],"Nicotine Addiction","Non-invasive deep brain stimulation","Temporal Interference Stimulation","BOLD Activation","2026-07-13",{"date":302,"type":37},"2026-07-15",{"date":304,"type":37},"2026-01-22",{"date":306,"type":23},"2027-02-27",{"name":308,"class":44},"Indiana University",2,{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":135,"enrollmentInfo":317,"targetDuration":4,"studyType":319,"phases":4,"briefSummary":320,"conditions":321,"keywords":328,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":45},"100645863","the-effect-of-comorbid-alcoholsubstance-use-100645863","NCT07692984","The Effect of Comorbid Alcohol\u002FSubstance Use","The Effect of Comorbid Alcohol\u002FSubstance Use on Social Inclusion and Clinical Outcome in Individuals With Severe Mental Illness Enrolled in a Community Mental Health Center: A Cross-Sectional Case-Control Study","Inclusion Criteria:\n\n* Being 18 years of age or older,\n* Having a diagnosis of Schizophrenia Spectrum Disorder and Other Psychotic Disorders or Bipolar Disorder according to DSM-5 diagnostic criteria,\n* Being actively followed up at the TRSM for at least 6 months.\n\nExclusion Criteria:\n\n* Individuals diagnosed with organic brain damage or neurodevelopmental disorders (intellectual disability, etc.),\n* Individuals with severe cognitive impairment that prevents them from communicating adequately.",{"count":318,"type":23},297,"OBSERVATIONAL","Study Design This study was designed as a comparative, cross-sectional case-control study examining the effect of comorbid alcohol and substance use disorder (ASUD) on clinical course and social inclusion among individuals with severe mental illness followed at a Community Mental Health Center (CMHC). The study did not involve any interventions.\n\nAim The aim of this study is to examine the effect of comorbid alcohol and substance use on clinical course parameters-such as number of hospitalizations and medication dosages-and on social inclusion indicators-such as employment, social participation, and social adjustment-among individuals with severe mental illness followed at the CMHC, in comparison with a matched control group without substance use.\n\nResearch Questions\n\nWhat are the rates of comorbid alcohol and substance use among patients with severe mental illness followed at the CMHC? What are the current addiction symptoms, number of hospitalizations, and employment rates among individuals with severe mental illness and comorbid ASUD? What is the level of continuity of CMHC engagement and social participation among individuals with severe mental illness and comorbid ASUD, and what factors influence it? How does the level of social inclusion among individuals with severe mental illness and comorbid ASUD compare with that of individuals without ASUD?\n\nHypotheses\n\nH1: The average annual number of hospitalizations among individuals with a dual diagnosis (severe mental illness + ASUD) followed at the CMHC is significantly higher than among those without substance use.\n\nH2: Among individuals with a dual diagnosis, the daily medication doses (e.g., chlorpromazine equivalents) required to control psychotic or manic symptoms are higher than in the control group.\n\nH3: Social inclusion is lower among patients with substance use compared with the control group.\n\nH4: Employment rates among individuals with a dual diagnosis are significantly lower than among those with severe mental illness alone.\n\nH5: Substance use negatively affects patients' social participation, including involvement in activities and friendships.\n\nH6: Attendance rates at CMHC workshops and rehabilitation programs are lower among individuals with substance use compared with the control group.",[322,323,32,324,325,326,327],"Alcohol Abuse","Alcohol Use Disorder","Severe Mental Disorder","Schizophrenia","Bipolar Disorder","Ostracism",[329,32,324,330],"alcohol use disorder","ostracism","2026-07-10",{"date":300,"type":37},{"date":334,"type":37},"2026-06-20",{"date":336,"type":23},"2026-12-30",{"name":338,"class":44},"Abant Izzet Baysal University",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":319,"phases":4,"briefSummary":349,"conditions":350,"keywords":352,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":45},"100610827","impact-of-federal-and-state-medications-for-opioid-use-disorder-moud-policy-changes-during-the-pandemic-100610827","NCT07232641","Impact of Federal and State Medications for Opioid Use Disorder (MOUD) Policy Changes During the Pandemic","Comparing Treatment Use, Retention, and Patient Outcomes Pre- and Post-implementation of Federal Policy Changes Regulating Buprenorphine and Methadone Treatment for Opioid Use Disorder","IMPACT","Inclusion Criteria:\n\n* Substance use disorder (alcohol and\u002For opioid) documented in the Veteran's Health Administration Corporate Data Warehouse (CDW)\n\nExclusion Criteria:\n\n* None",{"count":348,"type":23},185810,"\"Gold-standard\" medications for opioid use disorder (MOUD) treatment combines FDA-approved medications, primarily methadone and buprenorphine, with behavioral therapies to provide \"whole-patient\" treatment. Prior to the pandemic, methadone and buprenorphine were subject to greater federal regulations than medications for other substance use disorders, including medication for alcohol use disorder (MAUD), which created barriers to MOUD initiation and retention. These barriers were exacerbated by physical distancing and diminished clinic capacities during the COVID-19 pandemic. To prevent healthcare disruption and expand access to MOUD treatment during the public health emergency, federal and state authorities implemented several MOUD policy changes during the pandemic to reduce barriers to MOUD initiation and retention, which subsequently became permanent.\n\nThis study is an evaluation of the impacts of these policies on treatment use, retention, and patient outcomes pre- and post-MOUD policy implementation.",[32,323,351],"Opioid Use Disorder",[353],"Medications for opioid use disorder (MOUD)","2026-07-01",{"date":356,"type":37},"2026-07-02",{"date":358,"type":37},"2026-06-30",{"date":360,"type":23},"2029-09",{"name":362,"class":44},"Boston University",{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":24,"phases":372,"briefSummary":373,"conditions":374,"keywords":377,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":385,"leadSponsor":387,"locationsCount":309},"100635627","supporting-treatment-access-and-recovery-in-re-entry-star-r-100635627","NCT07555145","Supporting Treatment Access and Recovery in Re-entry (STAR-R)","STAR-R","Inclusion Criteria:\n\n* 18 years or older;\n* Proficient in reading and writing in the English language;\n* Are released from one of the participating jail\u002Fs; and\n* Have a current co-occurring substance use and mental health disorder, which includes both any substance use disorder (including alcohol) and mental health disorder (including depression, anxiety, trauma related disorders, bipolar, and\u002For schizophrenia) as documented by the participating jails.\n\nExclusion Criteria:\n\n* Are acutely suicidal based on the CSSRS; or\n* Are acutely psychotic (as this would require a higher level of care) based on SCID-5-RV.",{"count":371,"type":23},240,[26],"This application is aimed at testing a multicomponent intervention called \"Maintaining Independence and Sobriety through Systems Integration, Outreach, and Networking-Criminal Justice (MISSION-CJ) or Peer Linkage Support post-release from two jails in Massachusetts for individuals with co-occurring substance use and mental health disorders (COD), given high rates of COD among incarcerated populations. The research will examine engagement in treatment, behavioral health outcomes, mediators and moderators, an economic analysis, and facilitators and barriers of MISSION-CJ implementation.",[375,32,376],"Mental Health","Co-occurring Mental and Substance Use Disorders",[378,379,380,381,65],"MISSION-CJ","co-occurring disorders","peer linkage support","mental health","2026-06-29",{"date":354,"type":37},{"date":71,"type":23},{"date":386,"type":23},"2030-08-31",{"name":388,"class":44},"University of Massachusetts, Worcester",{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":397,"enrollmentInfo":398,"targetDuration":4,"studyType":24,"phases":399,"briefSummary":400,"conditions":401,"keywords":405,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":45},"100622759","clinical-and-neurobehavioral-changes-with-weight-loss-drug-discontinuation-and-reinitiation-100622759","NCT07387796","Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation","Clinical and Neurobehavioral Changes With GLP-1 (Glucagon-like Peptide-1) Discontinuation","CLIN-GLP1","Inclusion Criteria:\n\n* Aged 18-70 years.\n* Currently on tirzepatide.\n* Currently receiving care from University of Texas- Southwestern (UTSW) Weight Wellness Clinic.\n* Cognitively capable of understanding and signing informed consent.\n* Be proficient in English.\n\nExclusion Criteria:\n\n* History of major neurological or psychiatric disorders, including substance use disorders that might confound brain imaging results (e.g., stroke, epilepsy, multiple sclerosis, schizophrenia, major depression requiring hospitalization).\n* Diagnosis of Type 2 Diabetes.\n* Current diagnosis of an eating disorder.\n* Use of medications affecting weight other than tirzepatide.\n* Pregnancy or breastfeeding.\n* MR contraindications:\n* Heart pacemaker, heart valve replacement, or aortic clips\n* Metal fragments in the eyes, skin, or elsewhere in the body\n* Brain clips or pieces of metal used in aneurysm surgery or intercranial bypass\n* Venous umbrella\n* Pieces of metal in the body resulting from work as a sheet-metal worker or welder\n* Clips placed in an internal organ\n* Prosthetic devices, such as middle ear, eye, joint, or penile implants\n* Joint replacement\n* Hearing aid that cannot be removed\n* Neurostimulator\n* Insulin pump\n* Shunts or stents\n* Metal mesh or coil implants\n* Metal plate, pin, screws, or wires, or any other metal implants","70 Years",{"count":137,"type":23},[26],"The goal of this clinical study with research procedures is to learn how stopping and restarting tirzepatide (a medication that helps regulate blood sugar and appetite) affects brain activity, behavior, and health in adults ages 18-70 who are currently taking tirzepatide. Specifically, the study aims to examine how a short pause in tirzepatide affects hunger, mood, sleep, and daily functioning; how stopping and restarting tirzepatide alters brain chemistry and brain responses to food-related images; and how these changes relate to health measures such as quality of life and emotional well-being. There is no comparison group; instead, researchers will assess changes within each participant across three time points: while taking tirzepatide, after stopping it for 3-4 weeks, and after restarting it for 6-8 weeks. Participants will attend three in-person visits lasting approximately 3-4 hours each, during which they will complete interviews, questionnaires, and cognitive tasks; provide a urine sample (pregnancy screening for females); undergo a brain scan using magnetic resonance imaging (MRI) and MR spectroscopy (MRS); and receive a kit to provide a small stool sample. Participants will also complete two brief check-in phone calls between visits and the online BrainHealth Index between sessions, which includes surveys and cognitive tasks. All changes to tirzepatide use will occur under the supervision of a study physician to support participant safety and comfort, and the total study duration is approximately 13 weeks.",[402,32,403,404],"Drug Discontinuation","Eating Behavior Changes","Tirzepatide",[404,402,32,403],"2026-06-24",{"date":408,"type":37},"2026-06-26",{"date":410,"type":23},"2026-06",{"date":412,"type":23},"2029-02",{"name":414,"class":44},"The University of Texas at Dallas",{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":103,"sex":18,"minAge":54,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":24,"phases":425,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":432,"locationsCount":435},"100377698","exablate-for-lifu-neuromodulation-in-patients-with-opioid-use-disorder-oud-andor-other-substance-use-disorders-suds-100377698","NCT04197921","Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and\u002For Other Substance Use Disorders (SUDs)","A Feasibility Clinical Trial of Exablate for Low Intensity Focused Ultrasound Neuromodulation in Patients With Opioid Use Disorder (OUD) and\u002For Other Substance Abuse Disorders (SUDs)","Inclusion Criteria:\n\n1. Males and non-pregnant females, age 18 - 60 years old\n2. Subject meets DSM-5 criteria for OUD and\u002For other SUDs including alcohol (assessed via the SCID-5) of at least two years duration\n3. Subject is currently receiving outpatient treatment from the WVU Comprehensive Opioid Addiction Treatment Program (COAT), Intensive Outpatient Program (IOP) or any other program which implements the COAT model; residential or inpatient treatment from the WVU Center for Hope and Healing or an affiliated WVU hospital; or receiving outpatient\u002Finpatient\u002Fresidential treatment from similar programs that are well known to the research team. If the subject is prescribed medication for AUD or OUD (e.g. buprenorphine-naloxone, naltrexone), they will be on a stable dose of the medication for the 7 days prior to the procedure. Stable is defined as within the therapeutic range but does not require same exact dose for 7 days.\n4. Subject has been off opioids and other illicit substances, except for cannabis, confirmed via urine toxicology screen\n5. The NAc is apparent on MRI such that treatment targeting can be performed directly (visible on MRI) and indirectly (using other anatomical structures for measurements)\n6. Subject is able to communicate sensations during the Exablate Transcranial procedure\n7. Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all study visits\n8. Subject is able to make own medical decisions as determined by the clinical team\n9. Subject has signed and received a copy of the approved informed consent form\n\nExclusion Criteria:\n\n1. Subjects who are taking medications which may adversely interact with MOUD (See Appendix B for full list). Being on one of these medications would not automatically exclude a participant from study participation, does not automatically exclude a prospective subject from study participation. If a prospective or current subject is taking any medication listed in Appendix B, the study investigator is responsible for determining whether the subject is eligible for inclusion or continued study participation.\"\n2. Subject with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices\n3. Subject with known intolerance or allergies to the MRI contrast agent gadolinium (GADOVIST®)\n4. Subject who are unable or unwilling to tolerate the required prolonged stationary position during treatment (approximately 2-3 hours)\n5. More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp\n6. Subject with implanted objects in the skull or the brain\n7. Subject diagnosed with advanced kidney disease or on dialysis\n8. Subject with impaired renal function with estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73m2\n9. Subject with known unstable cardiac status or severe hypertension including:\n\n   1. Documented myocardial infarction within six months of enrollment\n   2. Unstable angina on medication\n   3. Unstable or worsening congestive heart failure\n   4. Left ventricular ejection fraction below the lower limit of normal\n   5. History of a hemodynamically unstable cardiac arrhythmia\n   6. Cardiac pacemaker\n   7. Severe hypertension (diastolic BP \\> 100 on medication)\n10. Subject with history of abnormal bleeding, hemorrhage, or coagulopathy\n11. Subject receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure\n12. Abnormal coagulation profile (PLT \\\u003C 100,000\u002Fμl), PT (\\>13.9 sec) or PTT (\\>37.5 sec), and INR \\> 1.2. If values are outside the range of normal limits, any clinically significant value may be excluded as determined by a study investigator.\n13. Subject with cerebrovascular disease as determined by MRI according to the Fazekas criteria. Grades II and III on the Fazekas scale should be excluded\n14. Past or present diagnosis of schizophrenia, psychotic disorder, bipolar disorder, or untreated depression other than one determined to be substance induced (assessed via SCID-5)\n15. Score of greater than 17 on the Hamilton Depression Rating Scale (HAM-D) or increased risk of suicide based on any positive response regarding passive or active suicidal ideation with or without intent over the past 3 months or lifetime history of active suicidal ideation with intent on the Columbia-Suicide Severity Rating Scale (C-SSRS) at baseline\n16. History of suicide attempt\n17. Parental history of completed suicide\n18. Subject meet the criteria for Cluster A or B Personality Disorders (assessed via SCID-5-PD)\n19. Diagnosis of dementia or any other disorder which has led to a clinically significant cognitive impairment (assessed via NIHTB-CB)\n20. Subject with brain tumors\n21. Subject with chronic pulmonary disorders e.g. severe emphysema, pulmonary vasculitis, or other causes of reduced pulmonary vascular cross-sectional area\n22. Any known CNS infection or infection with the Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV). A diagnosis of Hepatitis C (HCV) alone is not exclusionary as long as hepatic function laboratory values are deemed not clinically significant by a study investigator and are ≤ 1.5 times the upper limit of normal.\n23. Subject who has had deep brain stimulation or a prior stereotactic ablation of the NAc, basal ganglia or thalamus\n24. Subject who has been administered botulinum toxins into the arm, neck, or face for 5 months prior to baseline\n25. Subject who is currently participating in another clinical investigation with an active treatment arm\n26. Subject unwilling to abstain from illicit substance use during the course of the study\n27. Subject is considered to be a poor surgical or study candidate, which may include, but is not limited to the following: any medical, social, or psychological problem that could complicate the required procedures and evaluations of the study in the judgment of the investigator\n28. Subject is non-English speaking\n29. Subject is pregnant or planning to be pregnant","60 Years",{"count":424,"type":23},29,[26],"The purpose of this clinical trial is to investigate Low Intensity Focused Ultrasound (LIFU) using the Exablate® Model 4000 Type 2.0\u002F2.1 as an adjunctive neuromodulatory treatment for OUD (Opioid Use Disorder) and\u002For other Substance Use Disorders (SUDs) by assessing its safety and tolerability in subjects with OUD.",[111,32],{"date":408,"type":37},{"date":430,"type":37},"2019-11-27",{"date":73,"type":23},{"name":433,"class":434},"InSightec","INDUSTRY",4,{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":24,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":435},"100610116","shared-decision-making-to-treat-or-prevent-stop-hiv-in-criminal-legal-involved-populations-r33-100610116","NCT07223398","Shared Decision Making to Treat Or Prevent (STOP) HIV in Criminal Legal Involved Populations (R33)","STOP (Shared Decision Making to Treat Or Prevent) HIV in Criminal Legal Involved Populations","Inclusion Criteria:\n\n* able to provide written informed consent in English or Spanish;\n* living in the community of Western, CT, Dallas and Tarrant Counties in TX and Madison County, KY (potential for Fayette county as well);\n* Those with current justice involvement (with in the past 12 months) (e.g., prison, jail, community supervision);\n* willing to have HIV testing to determine negative or positive status;\n* persons with HIV who report not currently taking ART in past 6 months OR persons who test negative for HIV who report not taking PrEP that have a PrEP indication in past 12 months, including (i) condomless sexual intercourse; and\u002For (ii) sharing IDU equipment with HIV positive or unknown status partner; and\u002For (iii) bacterial STI and;\n* Having a history of opioid and\u002For stimulant use in the last 12 months within the community.\n\nExclusion Criteria:\n\n* severe medical or psychiatric disability making participation unsafe;\n* unable to provide consent.\n* persons self-reporting pregnancy",{"count":444,"type":23},400,[26],"This study seeks to compare the effectiveness of two Patient Navigation models of care to evaluate the proportion who initiate PrEP\u002FART and substance use\u002Fsubstance use disorder (SU\u002FSUD) treatment. A standardized Patient Navigation (PN) arm will be compared with a shared decision-making model in the form of Patient Choice (PC) through the offer of a menu of existing community-based health service delivery options. This design will offer providers, correctional and public health authorities, payers and policy makers' timely and relevant data to assess the effectiveness of Patient Navigation and Patient Choice models of care as potentially useful re-entry and relapse prevention treatment options.",[32],"2026-06-22",{"date":450,"type":37},"2026-06-25",{"date":452,"type":37},"2025-11-24",{"date":454,"type":23},"2028-06",{"name":456,"class":44},"Yale University",{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":24,"phases":467,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":309},"100511043","mitigating-the-impact-of-stigma-and-shame-among-people-living-with-hiv-and-substance-use-disorders-100511043","NCT05934305","Mitigating the Impact of Stigma and Shame Among People Living With HIV and Substance Use Disorders","Mitigating the Impact of Stigma and Shame as a Barrier to Viral Suppression Among People Living With HIV and Substance Use Disorders","MATTER","Inclusion Criteria:\n\n* HIV+\n* Meet criteria for an illicit (not solely including tobacco, cannabis, or alcohol) SUD\n* Endorse internalized stigma related to HIV, substance use, sexual orientation, or gender-identity\n* Either the participant reports a detectable viral load during past year OR if on oral ART, they report \\\u003C80% adherence in the past month OR if on oral ART, they report missing \\>=7 days of ART in any month in the past year OR for those on long acting injectable (LAI) ART, they report a period of \\>=14 days in the past year between LAI ART injections OR has a detectable HIV viral load (\\>20 copies\u002F mL) in the past year confirmed by medical records or viral load test from blood drawn obtained as part of the baseline visit\n* Provide informed consent in English\n* Verbally communicate and read in English or Spanish\n* Be ≥18 years old\n* Provide evidence or documentation of HIV+ status\n* Release HIV-related health records\n* Have access to a cell phone with text capacity (study will supplement phones and plans as needed consistent with our pilot work).\n\nExclusion Criteria:\n\n\\- HIV-",{"count":466,"type":23},256,[26],"People living with HIV and substance use disorders (SUDs) are less likely to be virally suppressed, which can lead to HIV transmission and negative health outcomes. This hybrid type 1 study will assess the efficacy, mechanisms, as well as facilitators and barriers to implementing the MATTER intervention, a virtually delivered 5-session text-enhanced psychobehavioral intervention designed to facilitate viral suppression by addressing internalized stigma and shame as barriers to engagement in HIV care among individuals living with HIV and SUDs in two locations with different levels of HIV resources (i.e., the Boston, Massachusetts and Miami, Florida metro areas). MATTER aims to mitigate the negative behavioral consequences of internalized stigma and shame on viral suppression by a) developing behavioral self-care goal setting skills and related self-efficacy, b) increasing metacognitive awareness (i.e., non-judgmental awareness of emotions and cognitions), and c) teaching and reinforcing compassionate self-restructuring (i.e., self- compassion), in addition to providing access to phone-based resource navigation. Scalable interventions such as MATTER are essential to our efforts to end the HIV epidemic in high priority regions.",[470,32],"Hiv",{"date":472,"type":37},"2026-06-23",{"date":474,"type":37},"2025-03-12",{"date":476,"type":23},"2028-06-30",{"name":362,"class":44},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":18,"minAge":486,"maxAge":20,"enrollmentInfo":487,"targetDuration":4,"studyType":24,"phases":489,"briefSummary":490,"conditions":491,"keywords":515,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":45},"100619125","neuroimaging-of-adolescent-cannabis-use-treatment-100619125","NCT07340554","Neuroimaging of Adolescent Cannabis Use Treatment","Neuroimaging of Instrumental Learning Networks in Adolescent Cannabis Use Treatment","ACT","Inclusion Criteria:\n\n* 14-17 year old youth\n* Guardian 18 years or older\n* Youth is MRI-eligible: No metal implants, prosthetics, orthodontic devices, transdermal medication patches, piercings and\u002For hair or eyelash extensions that cannot easily be removed, metallic ink tattoos on the neck or face, or claustrophobia, and are not pregnant\n* Youth must endorse having used cannabis at least once per week over the past month OR youth must have been diagnosed with cannabis use disorder within the past three months\n\nExclusion Criteria:\n\n* Youth has a history of Fetal Alcohol Spectrum Disorder, intellectual disorders, pervasive development disorder or autism spectrum disorder, psychotic disorders, history of neurological problems (epilepsy, traumatic brain injury, brain tumor, cerebrovascular disease) by parent\u002Fguardian report\n* Youth or caretaker who is monolingual non-English speaker\n* Youth who is currently experiencing active psychosis symptoms or suicidal\u002Fhomicidal ideation or who has been hospitalized within the past 6 months for psychosis or suicidality\u002Fhomicidality\n* Youth who is currently undergoing contingency management treatment for cannabis use disorder","14 Years",{"count":488,"type":23},80,[26],"This study is testing whether brain activity related to learning can help predict how well teens respond to a treatment program designed to reduce cannabis use. Teens ages 14-17 will complete a brain scan and then take part in 10 weekly virtual sessions where they report cannabis use and complete drug tests at home. Participants can earn prizes for staying cannabis-free.",[29,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506,507,508,509,510,31,32,511,512,513,514],"Cannabis Dependence","Cannabis Use Disorder","Cannabis Abuse","Cannabis Intoxication","Cannabis Smoking","Cannabis Withdrawal","Cannabis-Related Disorder","Cannabis Abuse, in Remission","Cannabis Abuse, Episodic Use","Marijuana","Marijuana Abuse","Marijuana Use","Marijuana Smoking","Marijuana Dependence","Marijuana User","Marijuana-Related Disorder","Marijuana Use Disorder","Addiction","Addiction, Substance","Substance Dependence","Substance Abuse","Substance Related Problem","Substance Abuse Drug Chronic",[516,501,509],"Cannabis","2026-06-18",{"date":448,"type":37},{"date":520,"type":37},"2026-06-15",{"date":522,"type":23},"2030-05-01",{"name":308,"class":44},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":103,"sex":18,"minAge":530,"maxAge":531,"enrollmentInfo":532,"targetDuration":4,"studyType":24,"phases":534,"briefSummary":535,"conditions":536,"keywords":538,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":45},"100501963","development-and-evaluation-of-a-virtual-reality-tool-for-at-risk-trauma-exposed-young-people-100501963","NCT05816083","Development and Evaluation of a Virtual Reality Tool for At-Risk Trauma-Exposed Young People","Inclusion Criteria for YMSM are as follows:\n\n* Someone who identifies as a YMSM or identifies as someone with romantic or physical attraction to individuals who identify as men\n* Is aged 15-30 years\n* Have experienced at least one ITE in lifetime (i.e., sexual assault, physical assault, witnessed domestic or community violence)\n* Report being consensually sexually active or planning to become sexually active with a partner in the next 12 months\n* Live in the Charleston, SC\u002FTri-county area\n\nInclusion Criteria for adolescents with SUD are as follows:\n\n* Someone who reports using substances in the past year (for participants ages 15-17) or the past 6 months (for participants ages 18-30)\n* Is aged 15-30 years\n* Have experienced at least one ITE in lifetime (i.e., sexual assault, physical assault, witnessed domestic or community violence)\n* Report being consensually sexually active or planning to become sexually active with a partner in the next 12 months\n* Live in the Charleston, SC\u002FTri-county area\n\nInclusion Criteria for front line healthcare workers are as follows:\n\n* works directly with adolescents who have experienced ITE and\u002For\n* works directly with adolescents or young adults with SUD and\u002For\n* works directly with YMSM and\u002For\n* works directly with and\u002For adolescent or young adults who are HIV-positive\n\nExclusion Criteria for all participants are as follows:\n\n* exhibits psychotic symptoms;\n* exhibits significant cognitive disability;\n* reports a history of Pervasive Developmental Disorder;\n* has active suicidal or homicidal ideations\n* self-reports high levels of motion sickness","15 Years","30 Years",{"count":533,"type":23},50,[26],"This is a multi-phased study, funded through a National Institute on Drug Abuse (NIDA) K24 grant that aims to ultimately refine a virtual reality tool through qualitative and quantitative research targeting HIV and substance abuse risk behavior among at-risk young people who have experienced psychosocial trauma. Participants eligible for this study include young men who have sex with men (YMSM)\u002Findividuals who are romantically\u002Fphysically attracted to men and adolescents with substance use disorder (SUD) between the ages of 15 - 30 and have experienced at least one traumatic event in their lifetime. Frontline healthcare workers who work within these populations are eligible for the study as well.",[32,537],"HIV Infections",[65,539,540,541,542,543],"alcohol use","substance use","HIV infections","HIV risk","virtual reality","2026-06-08",{"date":546,"type":37},"2026-06-10",{"date":548,"type":37},"2025-02-06",{"date":550,"type":23},"2026-11-30",{"name":43,"class":44},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":559,"enrollmentInfo":560,"targetDuration":4,"studyType":24,"phases":562,"briefSummary":563,"conditions":564,"keywords":566,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":581,"locationsCount":45},"100614566","tan-for-substance-use-disorder-100614566","NCT07281261","tAN for Substance Use Disorder","Study of Transcutaneous Auricular Neurostimulation as a Treatment for Substance Use Disorder","Inclusion Criteria:\n\n1. Male or female (evenly recruited) aged 18-64 years old\n2. Meeting DSM-5 criteria of moderate or above AUD at screening using the structured clinical interview for DSM-5 (SCID-5)\n3. Demonstration of at least moderate risk of alcohol use at screening using the WHO-ASSIST\n4. Demonstration of high risk for moderate to severe alcohol withdrawal syndrome (Prediction of Alcohol Withdrawal Severity Scale \\[PAWSS\\] \\> 4 at admission)\n5. Demonstration of severe withdrawal symptoms (Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised \\[CIWA-Ar\\] ≥ 8 at screening)\n6. Positive urine test for alcohol at screening\n7. Be able to provide written informed consent\n8. Female subjects must be non-nursing and not pregnant\n9. Meet the MRI safety screening form provided by the Center for Advanced MR Imaging (CAMRI) at BCM.\n\nExclusion Criteria:\n\n1. In the opinion of the clinician and the research team at admission, be expected to fail to complete the study protocol due to probably relocation from The Menninger Clinic area or not tolerable to receive tAN\n2. Current use of tobacco\n3. Is pregnant or nursing\n4. Contraindications to MRI (pacemaker, cochlear implants, metal in eyes, other metal implants, etc.)\n5. Do not meet the pre-screening MRI questions provided by the Center for Advanced MR Imaging (CAMRI) at BCM","64 Years",{"count":561,"type":23},20,[26],"The study will involve a 5-day tAN treatment to attenuate alcohol withdrawal syndrome (AWS) and alter resting state functional connectivity (RSFC) between OFC and striatum in patients with alcohol use disorder (AUD). Enrolled participants will wear the tAN device on-site (at The Menninger Clinic) for the 5-day detox treatment period. Participants with AUD will be single-blinded randomized into 2 groups - a treatment group (active tAN) and a placebo group (sham tAN). Each group will consist of five separate time points - admission, screening, baseline, tAN treatment, and post tAN treatment. Clinical measures collected before, during, and after treatment will include alcohol withdrawal severity, craving, benzodiazepine usage, and assessments of depression and suicidal behaviors. Participants will undergo MRI scans before and after the treatment period to assess changes in brain connectivity and their relationship to clinical outcomes.",[323,322,32,565],"Substance Use Disorders Alcohol Use Withdrawal State",[567,323,568,569,570,571,572,573,574],"Alcohol","Substance Use Disorder","Transcutaneous Auricular Neurostimulation","tAN","Neurostimulation","Vagus Nerve Stimulation","Auricular Neurostimulation","Transcutaneous","2026-06-01",{"date":577,"type":37},"2026-06-02",{"date":579,"type":37},"2026-01-28",{"date":125,"type":23},{"name":582,"class":434},"Spark Biomedical, Inc.",{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":590,"targetDuration":4,"studyType":24,"phases":592,"briefSummary":593,"conditions":594,"keywords":596,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":45},"100604216","efficacy-of-an-emdr-app-for-ptsd-and-sud-100604216","NCT07146633","Efficacy of an EMDR App for PTSD and SUD","Efficacy and Feasibility of Autonomous Eye Movement Desensitization and Reprocessing (A-EMDR) for Patients With Posttraumatic Stress Disorder (PTSD) and Substance Use Disorders","Inclusion Criteria:\n\n* Aged 18-years old or older\n* Fluent in English\n* Diagnosed with PTSD by the PTSD Checklist for DSM-5 (PCL-5 past month version score \\>32)\n* Diagnosed with past-year substance use disorder other than caffeine by structured clinical interview for DSM-5 (SCID-5)\n* Agrees not to participate in other treatments during the study duration (e.g., mindfulness, yoga, biofeedback, self-hypnosis or tai chi) except individuals who have been already on continuous therapies for at least three months\n\nExclusion Criteria:\n\n* Diagnosis of a severe or unstable mental illness that precludes safe participation in the study by a healthcare practitioner such as acute psychosis or mania diagnosed by a healthcare practitioner\n* Current suicidality risk as indicated during the conduct of the Columbia Suicide Severity Rating Scale (C-SSRS) (21) with concurrence after a study physician's evaluation if the response to C-SSRS questions 1 or 2 is \"yes\"",{"count":591,"type":23},24,[26],"The current proposal is aimed to confirm the efficacy of this novel therapeutic method (autonomous eye movement desensitization and reprocessing; A-EMDR) in a patient group (PTSD and SUD), and to assess the feasibility of the application within this group. While there is no basis to assume lower efficacy of the treatment with this population, confirming that hypothesis is an important and helpful step before a full-performance research study can be initiated. Furthermore, this study proposal will provide additional information regarding the feasibility for this population, which will allow for a more tailored approach in future study.",[595,32],"Posttraumatic Stress Disorder (PTSD)",[597,193,598],"EMDR","substance dependence","2026-05-20",{"date":601,"type":37},"2026-05-22",{"date":603,"type":37},"2026-01-20",{"date":605,"type":23},"2027-01-30",{"name":607,"class":44},"Centre for Addiction and Mental Health",{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":103,"sex":616,"minAge":530,"maxAge":617,"enrollmentInfo":618,"targetDuration":4,"studyType":24,"phases":620,"briefSummary":621,"conditions":622,"keywords":624,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":643,"locationsCount":309},"100561090","the-collaborative-care-prtner-study-100561090","NCT06585631","The Collaborative Care PrTNER Study","The Collaborative Care PrTNER (Prevention, Treatment, Navigation, Engagement, Resource) Project","PrTNER","Inclusion Criteria:\n\nAim 1:\n\n* 15-24 years old;\n* Cisgender male;\n* History of condomless sex;\n* Moderate-to-high risk SU behaviors based upon a Car, Relax, Alone, Forget, Friends, Trouble (CRAFFT) score ≥2,\n* Living in Philadelphia, PA or Baltimore, MD, and surrounding areas;\n* Able to read and write in English\n\nAim 2:\n\n* 15-29 years old;\n* Cisgender male;\n* Living with a diagnosis of HIV;\n* CRAFFT score ≥2,\n* Living in Philadelphia, PA or Baltimore, MD, and surrounding areas;\n* Able to read and write in English\n\nAim 3\n\n• All randomized study participants will be included in Aim 3.\n\nExclusion Criteria:\n\nAim 2:\n\n* Participants will be excluded if they are:\n* Assigned female sex at birth\n* Identify as transgender\n* Outside the age criteria (\\\u003C15 or \\>29 years old)\n* Cognitively unable to complete study requirements\n* Living outside of the two geographic areas\n* Do not screen positive for SU\n* No prior substance use history\n* No prior condomless sex;\n* Unable to read or write in English,\n* Plan to move in the next 12 months.","MALE","29 Years",{"count":619,"type":23},275,[26],"A randomized controlled trial to assess the ability of a Collaborative Care Prevention, Treatment, Navigation, Engagement, Resource (PrTNER) intervention to increase initiation of preexposure prophylaxis (PrEP) (for those at-risk for HIV) and decrease viral load (for those living with HIV) among young aged 15 to 29 through engagement in SU treatment.",[113,32,31,623],"AIDS",[113,623,625,626,627,539,628,629,630,631,632,633,634,635,636],"Substance use","Substances use disorder","drug use","preexposure prophylaxis","PrEP","peer coaches","community health worker","young men","adolescents","young male","young males","adolescent males","2026-05-15",{"date":639,"type":37},"2026-05-18",{"date":641,"type":37},"2025-01-02",{"date":476,"type":23},{"name":644,"class":44},"Children's Hospital of Philadelphia",{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":649,"acronym":650,"eligibilityCriteria":651,"healthyVolunteers":103,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":652,"targetDuration":4,"studyType":24,"phases":654,"briefSummary":655,"conditions":656,"keywords":663,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":668,"lastUpdatePostDateStruct":669,"startDateStruct":671,"completionDateStruct":672,"leadSponsor":674,"locationsCount":4},"100632905","recovery-inspired-support-engagement-rise-pilot-100632905","NCT07519759","Recovery Inspired Support Engagement (RISE) Pilot","(RISE)","Inclusion Criteria:\n\n* Inclusion Criteria for Support Persons:\n\n  * Ages 18+.\n  * Having a loved one who participated in an inpatient or residential substance use disorder program in the past 30 days, as reported by loved one, support person, clinician, or chart review.\n  * Interest in supporting the loved one's recovery from substance use.\n  * At least 4 days per month virtual or in-person contact per month with the loved one.\n  * Access to a computer with internet or mobile phone with video conferencing capabilities.\n  * Ability to provide written informed consent.\n  * Speak and read English.\n* Inclusion Criteria for Loved Ones:\n\n  * Ages 18+.\n  * Participated in an inpatient or residential substance use disorder program in the past 30 days, as reported by self, support person, clinician, or chart review.\n  * At least 4 days per month virtual or in-person contact per month with the support person.\n  * Access to a computer with internet or mobile phone with video conferencing capabilities.\n  * Ability to provide written informed consent.\n  * Speak and read English.\n\nExclusion Criteria:\n\n* Exclusion Criteria for Support Persons:\n\n  * DSM-5 moderate or severe substance use disorder in the past year.\n  * History of domestic violence with the loved one that would interfere with the ability to safely follow through with the intervention plan.\n  * Psychiatric, cognitive, or medical impairments that would interfere with the ability to follow through with the intervention plan.\n  * Prior participation of a support person of the loved one in an ITC-related research study.\n  * Significant prior experience with ITC or CRAFT (e.g., having completed an ITC-related training workshop or course prior to study enrollment)\n* Exclusion Criteria for Loved Ones: N\u002FA",{"count":653,"type":23},18,[26],"The goal of this clinical trial is to learn if a 1-on-1 support program is easy to complete and acceptable for people supporting loved ones who have recently received treatment for substance use. The main questions it aims to answer are:\n\nHow many people complete the program? How satisfied are people with the program?\n\nParticipants will:\n\nComplete weekly telehealth sessions for 12 weeks Complete surveys\u002Finterviews at the beginning, in the middle (\\~week 6), at the end of the program (\\~week 12), and 12-weeks after the end of the program Complete a focus group or interview",[657,658,659,660,661,662,32],"Support Persons","Family Members","Chosen Family","Romantic Partners","Friends","Caregivers",[657,661,32,567,664,665,169,666,667,660,659,658,662],"Substance Use (Drugs, Alcohol)","Social Support","Invitation to Change","ITC","2026-04-23",{"date":670,"type":37},"2026-04-28",{"date":354,"type":23},{"date":673,"type":23},"2028-02-28",{"name":675,"class":44},"Mclean Hospital",{"id":677,"slug":678,"hasResults":12,"nctId":679,"briefTitle":680,"officialTitle":681,"acronym":4,"eligibilityCriteria":682,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":683,"targetDuration":4,"studyType":24,"phases":685,"briefSummary":686,"conditions":687,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":689,"lastUpdatePostDateStruct":690,"startDateStruct":692,"completionDateStruct":694,"leadSponsor":696,"locationsCount":45},"100609808","peer-delivered-behavioral-activation-in-a-ccbhc-100609808","NCT07219394","Peer-Delivered Behavioral Activation in a CCBHC","Hybrid Effectiveness-Implementation Trial to Evaluate a Scalable, Peer-Delivered Intervention for Depression Among People With Substance Use Disorder in a Certified Community Behavioral Health Clinic","Inclusion Criteria:\n\n* Age 18 years old or older\n* Report clinically-significant symptoms of depression, as indexed by a score of 8+ on the PHQ-9.\n\nExclusion Criteria:\n\n* Active, under treated psychotic symptoms or mania that would interfere with participation in study procedures\n* Inability to provide informed consent and\u002For complete procedures in English",{"count":684,"type":23},250,[26],"Low-income individuals have limited access to evidence-based interventions for mental health. Peer recovery specialists, individuals in recovery from mental health and\u002For substance use problems, have the potential to increase access to evidence-based interventions for individuals from low-resource communities, particularly when trained and supervised in models that are acceptable and feasible in these communities. This study will examine the effectiveness and implementation potential of a peer-delivered evidence-based intervention (Behavioral Activation) among individuals receiving services from a community-based treatment setting providing integrated physical and behavioral healthcare.",[688,32],"Major Depressive Disorder","2026-04-15",{"date":691,"type":37},"2026-04-17",{"date":693,"type":23},"2026-05-01",{"date":695,"type":23},"2029-01-15",{"name":697,"class":44},"Wayne State University"]